Note 26 - Segment Information (Tables)

12 Months Ended

Dec. 31, 2016

Notes Tables

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

	2016			2015			2014
Segment operating income (loss)		392			488			(1,736	)
Financial income (expense), net		3,949			(2,094	)		1,771
Foreign Currency exchange (losses) gains, net		103			699			(431	)
Other income (expense), net		-			-			-
Income tax (expense) credit		(602	)		(759	)		(116	)
Consolidated net profit (loss)		3,842			(1,667	)		(512	)

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	HIFU Division			UDS Division			EDAP TMS (Corporate)			FDA		Total consolidated
2016
Sales of goods		9,382			14,664			-			-		24,045
Sales of RPPs & leases		3,547			1,359			-			-		4,906
Sales of spare parts and services		862			5,766			-			-		6,628
Total sales		13,791			21,789			-			-		35,579
External other revenues		28			4			-			-		32
Total revenues		13,819			21,792								35,611
Total COS		(5,710	)		(13,490	)		-			-		(19,200	)
Gross margin		8,109			8,302			-			-		16,411
R&D		(2,452	)		(1,416	)		-			-		(3,868	)
Selling and marketing expenses		(3,888	)		(4,968	)		-			-		(8,856	)
G&A		(804	)		(1,177	)		(1,315	)		-		(3,296	)
Total expenses		(7,144	)		(7,560	)		(1,315	)		1		(16,019	)
Operating income (loss)		964			742			(1,315	)		1		392
Total Assets		11,680			24,202			10,709			-		46,591
Capital expenditures		1,013			608			-			-		1,621
Long-lived assets		1,775			3,812			192			-		5,779
Goodwill		645			1,767			-			-		2,412

	HIFU Division			UDS Division			EDAP TMS (Corporate)			FDA			Total consolidated
2015
Sales of goods		4,878			17,027			-			-			21,906
Sales of RPPs & leases		2,908			1,501			-			-			4,408
Sales of spare parts and services		658			5,246			-			-			5,904
Total sales		8,444			23,774			-			-			32,218
External other revenues		32			3			-			-			35
Total revenues		8,476			23,777			-			-			32,253
Total COS		(3,636	)		(14,832	)		-			-			(18,468	)
Gross margin		4,841			8,945			-			-			13,785
R&D		(1,387	)		(992	)		-			(311	)		(2,690	)
Selling and marketing expenses		(2,284	)		(5,122	)		-						(7,406	)
G&A		(646	)		(1,192	)		(1,363	)					(3,202	)
Total expenses		(4,318	)		(7,306	)		(1,363	)		(311	)		(13,298	)
Operating income (loss)		523			1,639			(1,363	)		(311	)		488
Total Assets		9,619			25,818			3,144			-			38,581
Capital expenditures		457			207			-			-			664
Long-lived assets		1,437			3,320			192			-			4,949
Goodwill		645			1,767			-			-			2,412

	HIFU Division			UDS Division			EDAP TMS (Corporate)			FDA			Total consolidated
2014
Sales of goods		5,270			11,625			-			-			16,895
Sales of RPPs & leases		2,170			1,787			-			-			3,957
Sales of spare parts and services		760			4,640			-			-			5,400
Total sales		8,200			18,052			-			-			26,252
External other revenues		518			15			-			-			533
Total revenues		8,718			18,067			-			-			26,785
Total COS		(3,683	)		(11,901	)		-			-			(15,584	)
Gross margin		5,035			6,166			-			-			11,201
R&D		(1,062	)		(646	)		-			(1,224	)		(2,932	)
Selling and marketing expenses		(2,151	)		(4,527	)		-			-			(6,678	)
G&A		(660	)		(1,153	)		(1,514	)		-			(3,328	)
Total expenses		(3,874	)		(6,326	)		(1,514	)		(1,224	)		(12,937	)
Operating income (loss)		1,162			(160	)		(1,514	)		(1,224	)		(1,736	)
Total Assets		7,468			20,778			3,715			193			32,154
Capital expenditures		464			569			-			-			1,033
Long-lived assets		1,410			3,300			192			-			4,902
Goodwill		645			1,767			-			-			2,412